MedTrace Logo

Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)

NCT00981708 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2021-04-30

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and activity of the combination of lenalidomide with intermediate dose dexamethasone and cyclophosphamide in patients with primary systemic (AL ) amyloidosis.

Conditions

  • Amyloidosis

Interventions

DRUG

Lenalidomide, Dexamethasone and Cyclophosphamide

Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day. Dexamethasone tablets on days 1 to 4. Dose 20 mg per day. Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day. The cycle is to be repeated every 28 days (4 weeks)

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    collaborator OTHER

  • University of Athens

    lead OTHER

Principal Investigators

  • Meletios A Dimopoulos, MD · University of Athens, School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2011-01-11
Completion
2016-01-11

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00981708 on ClinicalTrials.gov